Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites
Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech market HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S.
Innovative Start-Up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ®
Leading academic center with multi-hospital and multi-state health system deepens Company’s footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) --
The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the Department of Defense, and the Indian Health Service HINGHAM, Mass., June 16, 2026
First Midwest-based account reflects continued execution of the Company's Full Market Release strategy and expansion into additional U.S. territories HINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY®
A leading academic center becomes the first user in the Southeast, Mid-Atlantic region HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it has secured its first
Israel becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions HINGHAM,
